Acute Watery Diarrhea with Markedly Elevated CRP and Leukocytosis – Evidence‑Based Diagnostic and Management Guidelines

1. Differential Diagnosis

• Bacterial gastroenteritis (invasive pathogens such as Salmonella, Campylobacter, Shigella, or enteroinvasive E. coli) is the leading cause when watery diarrhea is accompanied by markedly high CRP and a WBC count of ~10 000/µL, producing neutrophil‑predominant leukocytosis. 1
• Clostridioides  difficile infection must be excluded in every patient with acute diarrhea, especially after recent antibiotic exposure or healthcare contact. [1][2]
• Active inflammatory bowel disease (ulcerative colitis or Crohn’s disease) is suggested when CRP > 20 mg/L together with ESR > 15 mm, conferring an ≈8‑fold higher risk of relapse. 3
• Norovirus remains the most common viral cause of acute gastroenteritis in adults, but it typically yields CRP < 50 mg/L and a lymphocyte‑predominant differential, making pure viral etiology unlikely in the presence of very high CRP. 1

2. Laboratory and Microbiologic Workup

• Obtain stool culture for Salmonella, Shigella, Campylobacter, and enterohemorrhagic E. coli before initiating antibiotics; cultures are positive in ≈31 % of patients with this presentation. 1
• Draw blood cultures prior to empiric therapy when systemic toxicity is present. [1][4]
• Test stool for C. difficile toxin or perform a nucleic‑acid amplification test (NAAT) on the same specimen. [1][2]
• Perform a complete blood count with differential: neutrophil predominance supports bacterial/inflammatory causes, whereas lymphocyte predominance favors viral infection. 1
• Measure fecal calprotectin (or lactoferrin) when the etiology is unclear; values > 30 µg/g have 100 % sensitivity for active Crohn’s disease versus irritable bowel syndrome, and values > 150–250 µg/g indicate significant mucosal inflammation. 3

3. Risk Stratification Using CRP

Evidence level: moderate (derived from diagnostic accuracy studies). 5

4. Indications for Endoscopic Evaluation

• Persistent diarrhea beyond 7–13 days despite appropriate therapy should prompt endoscopic assessment. 1
• Severe clinical features—persistent bloody stools, systemic toxicity, or strong suspicion for IBD—are additional triggers for colonoscopy or flexible sigmoidoscopy with biopsies to differentiate IBD from infectious colitis. 2
• Markedly elevated fecal calprotectin (>150–250 µg/g) further supports the need for endoscopic investigation. 3

5. Management Considerations

• Empiric antibiotics may be started in severely ill patients, but stool and blood cultures must be obtained first. [1][4]
• Non‑steroidal anti‑inflammatory drugs (NSAIDs) can exacerbate IBD and provoke inflammatory diarrhea; avoid or discontinue them in suspected IBD. 2
• Recent antibiotic exposure markedly increases the risk of C. difficile infection; maintain a high index of suspicion and test promptly. [1][2]
• Immunosuppressed individuals have a broader differential that includes CMV colitis and other opportunistic infections, and they are at higher risk for both C. difficile and CMV colitis when they have underlying IBD. 3

All statements are derived from peer‑reviewed sources indicated by the citation IDs. Strength of evidence is noted where diagnostic performance metrics are provided.

Diagnostic Approach to Infectious Diarrhea

Limitations of Fecal Leukocyte Testing

• The presence of white blood cells in stool suggests inflammatory diarrhea, but this distinction has limited clinical utility in modern practice, according to the Infectious Diseases Society of America 6, 7
• Fecal leukocyte examination performs poorly to establish the infectious cause of diarrhea, especially among hospitalized patients, with significant technical limitations 6, 7
• Fecal leukocyte morphology degrades during transport and processing, making accurate recognition and quantitation difficult 6, 7
• In inflammatory diarrhea, fecal leukocytes are intermittently present and unevenly distributed in stool, significantly limiting sensitivity 6, 7
• Fecal leukocytes can be present in both infectious and non-infectious conditions, including inflammatory bowel disease, resulting in low specificity 6, 7

Alternative Testing

• The American Gastroenterological Association recommends using stool lactoferrin or calprotectin instead of fecal leukocytes to differentiate inflammatory from non-inflammatory diarrhea 6, 7
• Lactoferrin is more stable than fecal leukocytes during transport and processing, though also present in inflammatory bowel disease and breast milk 6, 7
• Calprotectin is an established marker of intestinal inflammation, though data for acute infectious diarrhea remain conflicting 6, 7, 8

Clinical Recommendations

• The Infectious Diseases Society of America advises against relying on fecal leukocytes alone to guide antibiotic therapy decisions 6, 7
• The American Gastroenterological Association recommends against using fecal leukocytes to distinguish between bacterial, viral, or parasitic causes of diarrhea 6, 7
• In breast-fed infants, lactoferrin is a normal component of human milk, making interpretation difficult in this population 6, 7
• Instead of fecal leukocyte examination, obtaining stool culture, C. difficile testing, and considering molecular pathogen panels is recommended for patients with suspected infectious diarrhea 6, 7
• For patients requiring risk stratification, stool calprotectin or lactoferrin can help identify those who may benefit from endoscopy or more aggressive workup, though these should not replace definitive microbiologic testing 8